Will Oklo Stock Double?
Oklo (NYSE: OKLO) is only a year removed from its SPAC‑enabled debut,…
Sell
34
WST Quote, Financials, Valuation and Earnings
Last price:
$224.54
Seasonality move
:
0.32%
Day range:
$225.42 - $228.58
52-week range:
$187.43 - $352.33
Dividend yield:
0.37%
P/E ratio:
35.66x
P/S ratio:
5.76x
P/B ratio:
6.08x
Volume:
465.5K
Avg. volume:
654.9K
1-year change:
-31.84%
Market cap:
$16.3B
Revenue:
$2.9B
EPS (TTM):
$6.37
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
WST
West Pharmaceutical Services
|
$725.3M | $1.51 | 3.28% | -0.47% | $278.84 |
|
BSX
Boston Scientific
|
$4.9B | $0.73 | 18.78% | 229.3% | $117.45 |
|
CATX
Perspective Therapeutics
|
$170.4K | -$0.29 | -- | -55.87% | $14.1071 |
|
GMED
Globus Medical
|
$739.7M | $0.76 | 16.49% | 239.13% | $85.17 |
|
PODD
Insulet
|
$612.3M | $0.93 | 25.31% | -64.13% | $336.01 |
|
TMCI
Treace Medical Concepts
|
$47.1M | -$0.29 | 5.9% | -21.86% | $10.02 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
WST
West Pharmaceutical Services
|
$227.18 | $278.84 | $16.3B | 35.66x | $0.21 | 0.37% | 5.76x |
|
BSX
Boston Scientific
|
$103.20 | $117.45 | $152.7B | 75.33x | $0.00 | 0% | 8.75x |
|
CATX
Perspective Therapeutics
|
$3.9800 | $14.1071 | $295.4M | -- | $0.00 | 0% | 28.05x |
|
GMED
Globus Medical
|
$57.12 | $85.17 | $7.7B | 42.63x | $0.00 | 0% | 3.15x |
|
PODD
Insulet
|
$289.32 | $336.01 | $20.4B | 52.04x | $0.00 | 0% | 9.73x |
|
TMCI
Treace Medical Concepts
|
$6.00 | $10.02 | $377.4M | -- | $0.00 | 0% | 1.77x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
WST
West Pharmaceutical Services
|
7.02% | 1.099 | 1.26% | 1.80x |
|
BSX
Boston Scientific
|
33.49% | 0.780 | 7.48% | 0.68x |
|
CATX
Perspective Therapeutics
|
-- | 1.363 | -- | -- |
|
GMED
Globus Medical
|
-- | 0.775 | -- | 2.60x |
|
PODD
Insulet
|
56.03% | 1.967 | 9.18% | 3.24x |
|
TMCI
Treace Medical Concepts
|
33.65% | 3.653 | 10.12% | 3.23x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
WST
West Pharmaceutical Services
|
$231.9M | $127.6M | 16.23% | 17.47% | 15.89% | $58.1M |
|
BSX
Boston Scientific
|
$3.2B | $937M | 6.35% | 9.57% | 19.02% | $277M |
|
CATX
Perspective Therapeutics
|
-- | -$21.8M | -- | -- | -- | -$26.2M |
|
GMED
Globus Medical
|
$402.7M | $98.1M | 4.22% | 4.59% | 16.4% | $136.2M |
|
PODD
Insulet
|
$409M | $88.8M | 15.79% | 36.9% | 10.07% | $48.1M |
|
TMCI
Treace Medical Concepts
|
$41.9M | -$15.6M | -32% | -47.17% | -27.79% | $655K |
West Pharmaceutical Services vs. Competitors
-
Which has Higher Returns WST or BSX?
Boston Scientific has a net margin of 12.87% compared to West Pharmaceutical Services's net margin of 14.45%. West Pharmaceutical Services's return on equity of 17.47% beat Boston Scientific's return on equity of 9.57%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services33.22% $1.23 $2.9B BSXBoston Scientific68.84% $0.45 $33.6B -
What do Analysts Say About WST or BSX?
West Pharmaceutical Services has a consensus price target of $278.84, signalling upside risk potential of 22.74%. On the other hand Boston Scientific has an analysts' consensus of $117.45 which suggests that it could grow by 13.81%. Given that West Pharmaceutical Services has higher upside potential than Boston Scientific, analysts believe West Pharmaceutical Services is more attractive than Boston Scientific.
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services9 2 0 BSXBoston Scientific23 2 0 -
Is WST or BSX More Risky?
West Pharmaceutical Services has a beta of 1.088, which suggesting that the stock is 8.813% more volatile than S&P 500. In comparison Boston Scientific has a beta of 0.679, suggesting its less volatile than the S&P 500 by 32.134%.
-
Which is a Better Dividend Stock WST or BSX?
West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.37%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or BSX?
West Pharmaceutical Services quarterly revenues are $698M, which are smaller than Boston Scientific quarterly revenues of $4.7B. West Pharmaceutical Services's net income of $89.8M is lower than Boston Scientific's net income of $674M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 35.66x while Boston Scientific's PE ratio is 75.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.76x versus 8.75x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services5.76x 35.66x $698M $89.8M BSXBoston Scientific8.75x 75.33x $4.7B $674M
-
Which has Higher Returns WST or CATX?
Perspective Therapeutics has a net margin of 12.87% compared to West Pharmaceutical Services's net margin of --. West Pharmaceutical Services's return on equity of 17.47% beat Perspective Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services33.22% $1.23 $2.9B CATXPerspective Therapeutics-- -$0.25 -- -
What do Analysts Say About WST or CATX?
West Pharmaceutical Services has a consensus price target of $278.84, signalling upside risk potential of 22.74%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.1071 which suggests that it could grow by 254.45%. Given that Perspective Therapeutics has higher upside potential than West Pharmaceutical Services, analysts believe Perspective Therapeutics is more attractive than West Pharmaceutical Services.
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services9 2 0 CATXPerspective Therapeutics10 1 0 -
Is WST or CATX More Risky?
West Pharmaceutical Services has a beta of 1.088, which suggesting that the stock is 8.813% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.701%.
-
Which is a Better Dividend Stock WST or CATX?
West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.37%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or CATX?
West Pharmaceutical Services quarterly revenues are $698M, which are larger than Perspective Therapeutics quarterly revenues of --. West Pharmaceutical Services's net income of $89.8M is higher than Perspective Therapeutics's net income of -$18.2M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 35.66x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.76x versus 28.05x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services5.76x 35.66x $698M $89.8M CATXPerspective Therapeutics28.05x -- -- -$18.2M
-
Which has Higher Returns WST or GMED?
Globus Medical has a net margin of 12.87% compared to West Pharmaceutical Services's net margin of 12.62%. West Pharmaceutical Services's return on equity of 17.47% beat Globus Medical's return on equity of 4.59%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services33.22% $1.23 $2.9B GMEDGlobus Medical67.33% $0.54 $4.1B -
What do Analysts Say About WST or GMED?
West Pharmaceutical Services has a consensus price target of $278.84, signalling upside risk potential of 22.74%. On the other hand Globus Medical has an analysts' consensus of $85.17 which suggests that it could grow by 49.1%. Given that Globus Medical has higher upside potential than West Pharmaceutical Services, analysts believe Globus Medical is more attractive than West Pharmaceutical Services.
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services9 2 0 GMEDGlobus Medical3 6 0 -
Is WST or GMED More Risky?
West Pharmaceutical Services has a beta of 1.088, which suggesting that the stock is 8.813% more volatile than S&P 500. In comparison Globus Medical has a beta of 1.193, suggesting its more volatile than the S&P 500 by 19.307%.
-
Which is a Better Dividend Stock WST or GMED?
West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.37%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or GMED?
West Pharmaceutical Services quarterly revenues are $698M, which are larger than Globus Medical quarterly revenues of $598.1M. West Pharmaceutical Services's net income of $89.8M is higher than Globus Medical's net income of $75.5M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 35.66x while Globus Medical's PE ratio is 42.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.76x versus 3.15x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services5.76x 35.66x $698M $89.8M GMEDGlobus Medical3.15x 42.63x $598.1M $75.5M
-
Which has Higher Returns WST or PODD?
Insulet has a net margin of 12.87% compared to West Pharmaceutical Services's net margin of 6.22%. West Pharmaceutical Services's return on equity of 17.47% beat Insulet's return on equity of 36.9%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services33.22% $1.23 $2.9B PODDInsulet71.88% $0.50 $3B -
What do Analysts Say About WST or PODD?
West Pharmaceutical Services has a consensus price target of $278.84, signalling upside risk potential of 22.74%. On the other hand Insulet has an analysts' consensus of $336.01 which suggests that it could grow by 16.14%. Given that West Pharmaceutical Services has higher upside potential than Insulet, analysts believe West Pharmaceutical Services is more attractive than Insulet.
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services9 2 0 PODDInsulet15 3 0 -
Is WST or PODD More Risky?
West Pharmaceutical Services has a beta of 1.088, which suggesting that the stock is 8.813% more volatile than S&P 500. In comparison Insulet has a beta of 1.346, suggesting its more volatile than the S&P 500 by 34.619%.
-
Which is a Better Dividend Stock WST or PODD?
West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.37%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or PODD?
West Pharmaceutical Services quarterly revenues are $698M, which are larger than Insulet quarterly revenues of $569M. West Pharmaceutical Services's net income of $89.8M is higher than Insulet's net income of $35.4M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 35.66x while Insulet's PE ratio is 52.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.76x versus 9.73x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services5.76x 35.66x $698M $89.8M PODDInsulet9.73x 52.04x $569M $35.4M
-
Which has Higher Returns WST or TMCI?
Treace Medical Concepts has a net margin of 12.87% compared to West Pharmaceutical Services's net margin of -30.29%. West Pharmaceutical Services's return on equity of 17.47% beat Treace Medical Concepts's return on equity of -47.17%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services33.22% $1.23 $2.9B TMCITreace Medical Concepts79.69% -$0.25 $158.8M -
What do Analysts Say About WST or TMCI?
West Pharmaceutical Services has a consensus price target of $278.84, signalling upside risk potential of 22.74%. On the other hand Treace Medical Concepts has an analysts' consensus of $10.02 which suggests that it could grow by 66.95%. Given that Treace Medical Concepts has higher upside potential than West Pharmaceutical Services, analysts believe Treace Medical Concepts is more attractive than West Pharmaceutical Services.
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services9 2 0 TMCITreace Medical Concepts2 4 0 -
Is WST or TMCI More Risky?
West Pharmaceutical Services has a beta of 1.088, which suggesting that the stock is 8.813% more volatile than S&P 500. In comparison Treace Medical Concepts has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock WST or TMCI?
West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.37%. Treace Medical Concepts offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Treace Medical Concepts pays out -- of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or TMCI?
West Pharmaceutical Services quarterly revenues are $698M, which are larger than Treace Medical Concepts quarterly revenues of $52.6M. West Pharmaceutical Services's net income of $89.8M is higher than Treace Medical Concepts's net income of -$15.9M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 35.66x while Treace Medical Concepts's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.76x versus 1.77x for Treace Medical Concepts. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services5.76x 35.66x $698M $89.8M TMCITreace Medical Concepts1.77x -- $52.6M -$15.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why a $5 Stock Is Suddenly a Cash Machine
If you stopped tracking Grab Holdings (NASDAQ: GRAB) after its 2021 SPAC…
Is Roku Stock Undervalued Now?
At roughly $89 a share, Roku (NASDAQ: ROKU) trades for barely…
Stock Ideas
Buy
69
Is NVDA Stock a Buy?
Market Cap: $4T
P/E Ratio: 56x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 43x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Alerts
Buy
58
INKT alert for Jul 14
MiNK Therapeutics [INKT] is down 36.03% over the past day.
Buy
51
NEGG alert for Jul 14
Newegg Commerce [NEGG] is down 26.42% over the past day.
Buy
68
ATRO alert for Jul 14
Astronics [ATRO] is down 1.02% over the past day.
